Life Science Executives Issue Call to Cut Business Ties with Russia
Various executives in the life sciences industry have started a petition calling for “complete economic disengagement” with Russia.
Various life sciences executives, including representatives from Ovid Therapeutics, Nkarta Therapeutics, and Alnylam Therapeutics, released a paper calling for fellow businesses to cease all business involvement with Russia. Until such a time that “restoration of peace and democracy [is achieved] in a sovereign Ukraine,” the authors ask that fellow businesses:
- Cease investment in Russian companies
- Reject Russian investments
- Halt collaboration or service agreements with Russian companies
- Halt trade in goods and services with Russian companies (except for food and medicines).
“We cannot look back in the future wondering whether we could have taken stronger measures.” reads the statement. “This justifies the strongest possible economic disengagement now.”
The authors encourage all industry professionals, not just executives or those working in the life sciences industry, to sign the agreement. As of March 9, 2022, more than 850 individuals have signed the agreement. The full list of co-signatories can be found here.
Source: Medium
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
